• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Treatment of tumor-bearing dogs with actinomycin D.

作者信息

Hammer A S, Couto C G, Ayl R D, Shank K A

机构信息

Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Ohio State University, Columbus.

出版信息

J Vet Intern Med. 1994 May-Jun;8(3):236-9. doi: 10.1111/j.1939-1676.1994.tb03224.x.

DOI:10.1111/j.1939-1676.1994.tb03224.x
PMID:8064663
Abstract

Fifty dogs with advanced malignancies were treated with actinomycin D at doses ranging from 0.5 to 1.1 mg/m2 every 3 weeks. The greatest number of responses was noted in dogs with lymphoma, including dogs that had received prior chemotherapy. Other responding tumor types included anal sac adenocarcinoma, perianal adenocarcinoma, squamous cell carcinoma, thyroid carcinoma, and transitional cell carcinoma. The median time to maximum response for dogs with lymphoma was 7 days, with a median duration of 42 days. Gastrointestinal toxicity was the most frequently observed side effect. A dose of 0.6 to 0.7 mg/m2 appears to be appropriate for treating various malignancies in dogs.

摘要

相似文献

1
Treatment of tumor-bearing dogs with actinomycin D.
J Vet Intern Med. 1994 May-Jun;8(3):236-9. doi: 10.1111/j.1939-1676.1994.tb03224.x.
2
Actinomycin D for reinduction of remission in dogs with resistant lymphoma.放线菌素D用于对耐药性淋巴瘤犬进行再诱导缓解治疗。
J Vet Intern Med. 1994 Sep-Oct;8(5):343-4. doi: 10.1111/j.1939-1676.1994.tb03247.x.
3
Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).放线菌素D作为复发或耐药性淋巴瘤犬的挽救疗法:49例(1999 - 2006年)
J Am Vet Med Assoc. 2008 Aug 1;233(3):446-51. doi: 10.2460/javma.233.3.446.
4
Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.含放线菌素-D的联合化疗方案联合延长维持治疗对犬淋巴瘤的评估。
Can Vet J. 2006 Jan;47(1):52-9.
5
Efficacy of mitoxantrone against various neoplasms in dogs.米托蒽醌对犬多种肿瘤的疗效。
J Am Vet Med Assoc. 1991 May 1;198(9):1618-21.
6
Phase II evaluation of doxorubicin for treatment of various canine neoplasms.阿霉素治疗各种犬类肿瘤的II期评估。
J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3.
7
The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.地塞米松、美法仑、放线菌素D和阿糖胞苷(DMAC)化疗方案对复发性犬淋巴瘤的疗效及不良事件情况
Can Vet J. 2014 Feb;55(2):175-80.
8
Randomized controlled trial of doxorubicin versus dactinomycin in a multiagent protocol for treatment of dogs with malignant lymphoma.多药联合方案中阿霉素与放线菌素D治疗犬恶性淋巴瘤的随机对照试验
J Am Vet Med Assoc. 1998 Oct 1;213(7):985-90.
9
Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.
Cancer Chemother Pharmacol. 2002 Mar;49(3):251-5. doi: 10.1007/s00280-001-0402-6. Epub 2001 Dec 18.
10
Clinical evaluation of methoximorpholino-doxorubicin (FCE 23762) in dogs with spontaneous malignancies.甲氧吗啉诺多柔比星(FCE 23762)对患有自发性恶性肿瘤犬的临床评估。
J Vet Intern Med. 2000 Jan-Feb;14(1):86-9. doi: 10.1892/0891-6640(2000)014<0086:ceomdi>2.3.co;2.

引用本文的文献

1
A Retrospective Study of Clinical and Histopathological Features of 81 Cases of Canine Apocrine Gland Adenocarcinoma of the Anal Sac: Independent Clinical and Histopathological Risk Factors Associated with Outcome.81例犬肛门囊顶泌汗腺腺癌的临床及组织病理学特征回顾性研究:与预后相关的独立临床及组织病理学危险因素
Animals (Basel). 2021 Nov 22;11(11):3327. doi: 10.3390/ani11113327.
2
Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.评估toceranib 治疗犬的大汗腺肛门囊腺癌。
J Vet Intern Med. 2020 Mar;34(2):873-881. doi: 10.1111/jvim.15706. Epub 2020 Jan 24.
3
Identification of the Actinomycin D Biosynthetic Pathway from Marine-Derived SCSIO ZS0073.
从海洋来源的 SCSIO ZS0073 中鉴定放线菌素 D 的生物合成途径。
Mar Drugs. 2019 Apr 23;17(4):240. doi: 10.3390/md17040240.
4
Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs.犬肛门囊顶泌汗腺腺癌手术切除后辅助卡铂化疗的评估
Vet Comp Oncol. 2016 Mar;14(1):67-80. doi: 10.1111/vco.12068. Epub 2013 Oct 24.
5
Early tumor response to intraarterial or intravenous administration of carboplatin to treat naturally occurring lower urinary tract carcinoma in dogs.犬自然发生的下泌尿道癌动脉内或静脉内给予卡铂后的早期肿瘤反应。
J Vet Intern Med. 2015 May-Jun;29(3):900-7. doi: 10.1111/jvim.12594. Epub 2015 Apr 21.
6
The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.地塞米松、美法仑、放线菌素D和阿糖胞苷(DMAC)化疗方案对复发性犬淋巴瘤的疗效及不良事件情况
Can Vet J. 2014 Feb;55(2):175-80.
7
Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs.亚硝酰钴胺素对犬自发性肿瘤的抗肿瘤作用。
Invest New Drugs. 2010 Oct;28(5):694-702. doi: 10.1007/s10637-009-9282-0. Epub 2009 Jun 27.
8
External beam radiation therapy for thyroid cancer in the dog.犬甲状腺癌的外照射放射治疗。
Can Vet J. 2007 Jul;48(7):761-3.
9
Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.含放线菌素-D的联合化疗方案联合延长维持治疗对犬淋巴瘤的评估。
Can Vet J. 2006 Jan;47(1):52-9.
10
Anal sac adenocarcinoma in a Siamese cat.一只暹罗猫的肛门囊腺癌。
J Feline Med Surg. 2002 Dec;4(4):205-7. doi: 10.1053/jfms.2002.0174.